ライフサイエンスコーパス: MMP-10

1 MMP-3 and MMP-10) and 3D cultures (MMP-9 and MMP-10).

2 (MAPT, NEFL) and tissue remodelling (TMSB10, MMP-10).

3 h MMP-3 and disrupt unique interactions with MMP-10.

4 d with a cathepsin inhibitor, cystatin C, or MMP-10.

5 r the inhibition of MMP-3 in preference over MMP-10.

6 tro, suggesting ZO-1 as a novel substrate of MMP-10.

7 a very potent and selective non-hydroxamate MMP-10/-13 inhibitor.

8 us to discover matrix metalloproteinase-10 (MMP-10), a secreted zinc-dependent endopeptidase, as one

9 from IL-1 plus OSM-stimulated cartilage, and MMP-10 activated proMMP-1, proMMP-8, and proMMP-13.

10 gnificantly increased sHB-EGF, inhibition of MMP-10 activity using a broad spectrum MMP inhibitor had

11 This study investigated trophoblast mediated MMP-10 and HB-EGF expression and determined if there was

12 l analysis confirmed increased expression of MMP-10 and MET in bronchial epithelial cells and in sube

13 ing stringent false discovery rate analysis, MMP-10 and MET were significantly overexpressed in biops

14 as matrix metalloproteinase (MMP)-1, MMP-3, MMP-10 and MMP-12, are key players in the development of

15 is of this new insight into the relevance of MMP-10 and MMP-13 within the MMP network and the ban of

16 induced expression of the HDAC7 target genes Mmp-10 and Nur77, and inhibits VEGF-induced vascular per

17 MMP-10 and PKCiota are coordinately overexpressed in pri

18 l relatively novel proteins, such as TMSB10, MMP-10 and SMOC2, which have potential as novel biomarke

19 hted induction of the matrix metalloprotease MMP-10 and the extracellular matrix protein mindin (enco

20 ore, the detectable levels of synovial fluid MMP-10 and the histologic detection of this proteinase i

21 was a relationship between the secretion of MMP-10 and the release of soluble HB-EGF (sHB-EGF) from

22 Transcription of MMP-10 and tissue inhibitor of metalloprotease 1 was inc

23 MPs in both fibroblast monolayers (MMP-3 and MMP-10) and 3D cultures (MMP-9 and MMP-10).

24 usly shown that matrix metalloproteinase 10 (MMP-10) and Heparin binding-EGF like growth factor (HB-E

25 lved a proteolytic axis composed of plasmin, MMP-10, and MMP-1.

26 of matrix metalloproteinase (MMP)-1, MMP-3, MMP-10, and MMP-13.

27 es in a matrix metalloproteinase-1 (MMP-1)-, MMP-10-, and ADAM-15 (a disintegrin and metalloproteinas

28 The high potency (IC50 of 31 nM [MMP-10] and 5 nM [MMP-13]) and selectivity over MMP-1, -

29 In contrast, MMP-1 and MMP-10 are strongly induced during EC tube formation to

30 As MMP-3 and MMP-10 are the most similar MMPs in sequence, structure,

31 Our findings support the use of CSF MMP-10 as a prognostic marker for dementia of the Alzhei

32 ation, and decreased production of mmp-3 and mmp-10 by human conjunctival fibroblasts.

33 To understand the regulation of MMP-10 by tissue inhibitors of metalloproteinases (TIMPs

34 MMP-1, MMP-3 and MMP-10 concentrations decreased with time after trauma (

35 Plasma MMP-1, MMP-8, and MMP-10 concentrations significantly decreased during tre

36 s, our findings illustrate that induction of MMP-10 could lead to podocyte injury by degrading ZO-1,

37 n alpha(3)beta(1), whereas in normal corneas MMP-10 decreased laminin-10 and integrin alpha(3)beta(1)

38 hanism where Piezo1 activity increased MMP-1/MMP-10, decreased collagen I and fibronectin, and increa

39 and cell-based models demonstrated that the MMP-10-dependent collagenolytic activity was a product o

40 Incubation of purified ZO-1 with MMP-10 directly resulted in its proteolytic degradation

41 One family member, MMP-10, directly cleaves Htt and prevents cell death whe

42 Knockdown of MMP-10 expression blocks anchorage-independent growth an

43 Immunohistochemistry assessed MMP-10 expression in diseased joint tissues.

44 negative PKCiota inhibits tumorigenicity and MMP-10 expression in subcutaneous NSCLC tumors.

45 expression inhibits NSCLC transformation and MMP-10 expression in vitro.

46 expressed in primary NSCLC tumors, and tumor MMP-10 expression predicts poor survival in NSCLC patien

47 ion of ADAMTS-5 expression and regulation of MMP-10 expression suggest complex and context-dependent

48 MMP-10 expression was confirmed in both chondrocytes and

49 MMP-10 expression was significantly lower in decidual ti

50 ulted in enhanced ADAMTS-5 expression, while MMP-10 expression was suppressed.

51 -deficient cells restores transformation and MMP-10 expression, whereas expression of Par6alpha mutan

52 invasion of NSCLC cells through induction of MMP-10 expression.

53 h activation of matrix metalloproteinase-10 (MMP-10) expression.

54 broblasts and articular chondrocytes express MMP-10 following treatment with procatabolic stimuli.

55 p-regulation of matrix metalloproteinase 10 (MMP-10) following treatment with the procatabolic stimul

56 1 variants bound to MMP-3 and counter-target MMP-10 how structural alterations within the N-terminal

57 to MMP-3, little is known about the role of MMP-10 in cartilage catabolism.

58 a demonstrate a critical role for macrophage MMP-10 in controlling the tissue remodeling activity of

59 Increased concentrations of MMP-2 and MMP-10 in CSF at baseline were associated with an unfavo

60 t SGHVMC-9, a human VSMC cell line, secreted MMP-10 in response to trophoblast conditioned medium (TC

61 in diseased joint tissues strongly implicate MMP-10 in the cartilage degradome during arthritis.

62 mmunohistochemistry revealed the presence of MMP-10 in the synovium and cartilage of an IL-1 plus OSM

63 In contrast, knockdown of MMP-10 in vivo protected mice from proteinuria, restored

64 sufficient to induce expression of MMP-9 and MMP-10, in a manner requiring its USP activity, but not

65 CSF MMP-10 increased the prediction accuracy of CSF amyloid-

66 Although MMP-10 is closely related to MMP-3, little is known abou

67 rpose of this study was to determine whether MMP-10 is expressed in connective tissue cells and to as

68 Matrix metalloproteinase-10 (MMP-10) is expressed by macrophages and epithelium in re

69 MET and MMP-10 likely play an important role in these processes.

70 siRNA suppression of MMP-1 and MMP-10 markedly blocks tube regression without affecting

71 MMP-10 may be implicated in H. pylori-mediated extracell

72 CSF level of MMP-10 may reflect ageing and neuroinflammation.

73 th H. pylori led to an increase in levels of MMP-10 messenger RNA, protein secretion, and activity.

74 P-2 for the active catalytic domain of human MMP-10 (MMP-10cd) using multiple kinetic approaches.

75 Novel targets, including MMP-8, MMP-10, MMP-14, MMP-19, MMP-25 and MMP-28, are also bein

76 MMP-10 modulation occurs via EGFR activation in a proces

77 of PML decreases basal and TNF-alpha-induced MMP-10 mRNA accumulation.

78 ciation between HDAC7 and MEF2 and decreases MMP-10 mRNA accumulation.

79 teinase (MMP)-10, leading to accumulation of MMP-10 mRNA.

80 MMP-10 overexpressed in the diabetic corneal epithelium

81 ic mice with podocyte-specific expression of MMP-10, proteinuria was aggravated after injury induced

82 Interestingly, MMP-10 reduced podocyte tight junctional protein zonula

83 Western blot analysis indicated that MMP-10 secreted by EC in response to IL-1beta stimulatio

84 kin-1beta (IL1beta) significantly stimulated MMP-10 secretion by SGHEC-7 cells.

85 MMP-10 secretion increased by 90% with binding to type I

86 sponded to CsA treatment with a reduction in MMP-10 secretion.

87 (IL-1Ra) significantly inhibited TCM-induced MMP-10 secretion.

88 f MEK and JNK in TCM and IL-1beta stimulated MMP-10 secretion.

89 ed CSF level of matrix metalloproteinase 10 (MMP-10) showed a higher probability of progressing to de

90 /or asthma, and matrix metalloproteinase-10 (MMP-10) showed the most significant associations.

91 Exogenous MMP-10 significantly enhanced collagenolysis from IL-1 p

92 Matrix metalloproteinase 10 (MMP-10, stromelysin-2) is a secreted metalloproteinase w

93 mRNA levels of matrix metalloproteinase-10 (MMP-10/stromelysin-2) were significantly elevated in DR

94 six of these markers (DDC, CRH, MMP-3, ABL1, MMP-10, THOP1) was developed and validated in independen

95 C cells and addition of catalytically active MMP-10 to PKCiota- or Par6alpha-deficient cells restores

96 The ability of MMP-10 to superactivate procollagenases that are relevan

97 Including MMP-10 to the [A/T/(N)] scheme improved considerably the

98 alloproteinase 7 [MMP-7]) and stromelysin-2 (MMP-10), two MMPs induced by acute P. aeruginosa pulmona

99 MMP-10 up-regulation was dependent on several MAPKs, but

100 MMP-10 was correlated with age in subjects with normal A

101 ther IL-1 plus OSM or TNFalpha plus OSM, and MMP-10 was detected in synovial fluid samples from patie

102 s down-regulated 9-fold, while expression of MMP-10 was up-regulated 14-fold, and these responses wer

103 ts with proteinuric chronic kidney diseases, MMP-10 was upregulated specifically in the podocytes of

104 MMP-10 was widely expressed in first trimester decidual

105 Synovial fluid levels of MMP-10 were determined by specific immunoassay.

106 CSF concentrations of MMP-1, MMP-3 and MMP-10 were increased in TBI patients (at baseline) comp

107 ases also had elevated circulating levels of MMP-10, which correlated with the severity of kidney ins

108 nvolved in inflammatory processes, including MMP-10, which is suggested to have a role in high type-2

109 ocks tube regression by inhibiting MMP-1 and MMP-10 while having no influence on EC tube formation.